Revenue, 2025

USD 1.42 Billion

Forecast, 2035

USD 5.38 Billion

CAGR, 2026-2035

14.24%

Report Coverage

United States

U.S. Automated Cell Counting Market Trends for 2026

The U.S. automated cell counting market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.62 billion in 2026 to approximately USD 5.38 billion by 2035, expanding at a CAGR of 14.24% from 2026 to 2035.

The market is growing due to increasing biotechnology research, expanding pharmaceutical development, and strong laboratory infrastructure. Rising demand for precise and rapid cell analysis in research and clinical laboratories is encouraging the adoption of automated cell counting technologies.

Key Takeaways

• United States automated cell counting industry poised to reach USD 1.62 billion by 2026.
• Forecasted to grow to USD 5.38 billion by 2035.
• Expected to maintain a CAGR of 14.24% from 2026 to 2035.
• By product, the consumables & accessories segment held a dominant position in the U.S. automated cell counting market in 2025.
• By product, the instruments segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By application, the cell line development segment registered dominance in the market in 2025.
• By application, the stem cell research segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By end use, the pharmaceutical & biotechnology companies segment led the market in 2025.
• By end use, the hospitals & diagnostic laboratories segment is expected to grow at the fastest CAGR in the market during the forecast period.

Strong Expansion of Life Science Research in the U.S.

The market refers to the industry focused on instruments and technologies used to automatically measure and analyze cell numbers and viability in laboratories across the United States for research, diagnostics, and biopharmaceutical applications. The U.S. automated cell counting market is growing due to increasing investments in biotechnology, pharmaceutical development, and cell-based research. Laboratories require accurate and rapid cell analysis to support drug discovery, biologics production, and clinical studies. Automated cell counting systems help improve efficiency, reduce manual workload, and ensure consistent results. In addition, the presence of advanced research infrastructure and rising demand for reliable laboratory technologies further support market growth.

The U.S. automated cell counting market is expanding due to widespread laboratory adoption of high-throughput screening tools. This growth is heavily supported by massive capital injections from private equity firms into early-stage biotechnology start-ups. Additionally, federal funding through National Institutes of Health grants is driving academic research centers to upgrade from manual hemocytometers to automated platforms.
Technologically, the industry is transitioning toward artificial intelligence and deep-learning software integration. These digital systems eliminate human bias, optimize focus algorithms, and accurately identify irregular cell morphology or debris clusters. Furthermore, the rising production of complex biologics, personalized cell therapies, and mRNA vaccines requires continuous, automated viability monitoring to ensure strict compliance with federal manufacturing safety protocols.

How Can AI Affect the U.S. Automated Cell Counting Market?

Artificial intelligence can enhance the market by improving the precision and efficiency of cell analysis. Advanced data processing tools help laboratories quickly interpret large volumes of cell imaging data, enabling faster research outcomes. These technologies can also streamline laboratory workflows, support consistent results, and assist researchers in identifying complex cell patterns, which strengthens their role in biotechnology, pharmaceutical research, and clinical laboratories across the United States.

Trend and Future Outlook of the U.S. Automated Cell Counting Market

• Strong Growth in Biopharmaceutical Research: The U.S. has a large number of biotechnology and pharmaceutical companies investing in biologics, vaccines, and cell-based therapies. This increases the need for reliable cell measurement tools. Automated cell counting systems help researchers monitor cell concentration and viability efficiently, supporting consistent results in drug development and laboratory research activities.
• Rising Adoption in Clinical and Diagnostic Laboratories: Hospitals and diagnostic laboratories are increasingly using automated cell counting devices to improve the speed and reliability of cell analysis. These systems reduce manual workload and provide consistent results, which is important for research and routine laboratory testing. As healthcare laboratories modernize their equipment, demand for automated cell counting technologies continues to grow.
• Advancements in Laboratory Instrument Design: Manufacturers are introducing automated cell counting instruments with improved digital interfaces, faster processing capabilities, and easier operation. These developments simplify laboratory workflows and make the technology more accessible for academic institutions, research centers, and small laboratories, supporting broader adoption across the U.S. life science research sector.

Executive Summary Table

Segmental Insights

By Product Insights

Why Did the Consumables & Accessories Segment Dominate in the U.S. Automated Cell Counting Market in 2025?

The consumables & accessories segment dominated the market in 2025 due to their frequent and repeated use in laboratory workflows. Items such as counting slides, reagents, and sample preparation materials must be regularly replaced, creating consistent demand. Growing research activities in biotechnology and pharmaceutical laboratories also increase the consumption of these products, supporting the segment’s leading market share.

Instruments

The instruments segment is expected to grow at the fastest CAGR in the market due to increasing adoption of advanced laboratory equipment in biotechnology and pharmaceutical research. Research institutions are investing in modern automated systems to improve efficiency, accuracy, and workflow productivity. In addition, continuous technological improvements and the growing need for high-performance cell analysis tools are encouraging laboratories to upgrade to advanced automated cell counting instruments.

By Application Insights

What Made the Cell Line Development Segment Dominant in the U.S. Automated Cell Counting Market in 2025?

The cell line development segment dominated the market in 2025 due to the increasing use of cultured cells in biologics production, vaccine research, and therapeutics development. Accurate monitoring of cell growth, viability, and concentration is essential during cell line optimization. Automated cell counting systems help researchers obtain reliable and consistent data, making them widely used in biotechnology and pharmaceutical laboratories involved in cell-based product development.

In January 2024, Abzena introduced a new cell line development platform named AbZelectPRO. The platform is designed to accelerate the creation of cell lines used in producing recombinant proteins and antibodies, helping improve efficiency in biopharmaceutical manufacturing.

Stem Cell Research

The stem cell research segment is expected to grow at the fastest CAGR in the market due to an increasing focus on regenerative medicine and advanced therapeutic development. Stem cell studies require precise monitoring of cell concentration and viability during experiments. Automated cell counting systems provide accurate and consistent measurements, which help researchers maintain quality and efficiency in stem cell culture, expansion, and clinical research applications.

By End Use Insights

How Does the Pharmaceutical & Biotechnology Companies Segment Dominate the U.S. Automated Cell Counting Market in 2025?

The pharmaceutical & biotechnology companies segment dominated the market in 2025 due to the extensive use of cell analysis in drug discovery, biologics production, and vaccine development. These companies require precise monitoring of cell growth and viability during the research and manufacturing process. Automated cell counting systems help improve accuracy, efficiency, and consistency in laboratory workflows, making them essential tools in pharmaceutical and biotechnology research facilities.

Hospitals & Diagnostic Laboratories

The hospitals & diagnostic laboratories segment is expected to grow at the fastest CAGR due to increased demand for accurate and rapid laboratory testing. Growing patient volumes and the need for efficient diagnostic procedures encourage healthcare facilities to adopt automated technologies. Automated cell counting systems help improve testing efficiency, reduce manual errors, and support reliable cell analysis in clinical diagnostic and routine laboratory workflows.

Regional Insights

The U.S. automated cell counting market is experiencing rapid growth, driven by increasing adoption in biopharma, oncology research, and clinical diagnostics, which demand higher accuracy, speed, and standardization.

California Market Trends

California's market thrives due to a high concentration of biotech firms and research institutions in the Bay Area. Robust funding for cell-based research, particularly in stem cells and oncology, drives the adoption of automated imaging systems for faster, more accurate cell viability, enhancing laboratory efficiency, and reducing reliance on manual counting.

Massachusetts

The Massachusetts market is growing rapidly, supported by the Boston area's extensive biotech, pharma, and academic research presence. Increased investment in cell therapy, gene therapy, and bioprocessing requires precise, high-throughput automated cell counters for quality control, propelling demand for sophisticated imaging, AI-based analytics, and associated consumables

Market Ecosystem Analysis

Supply Chain Analysis

R&D

• Research and development activities in automated cell counting in the United States are expanding as laboratories require faster, more accurate, and standardized methods for cell analysis. Increasing work in biopharmaceutical research, stem cell studies, and clinical diagnostics is encouraging innovation in advanced cell counting technologies.
• Key players: Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Merck KGaA, and Agilent Technologies.

Clinical Trials

• Clinical studies in the United States are increasingly evaluating automated cell counting systems to confirm their accuracy and reliability in laboratory and clinical applications. These trials focus on improving the measurement of low-concentration samples and supporting areas such as stem cell production. The goal is to replace time-consuming manual counting techniques with faster and more consistent automated solutions.
• Key players: ChemoMetec, Logos Biosystems, DeNovix, Nexcelom Bioscience, and NanoEntek.

Serialization

• Serialization in automated cell counting focuses on maintaining accurate data records, traceability, and compliance with regulatory standards used in research and GMP laboratory environments. Automated systems generate unique and traceable sample identifiers, which help laboratories track results, manage data efficiently, and reduce the risk of sample or data errors.
• Key players: Beckman Coulter, Eppendorf, Becton, Dickinson and Company, PerkinElmer, and Tecan Group.

Top Vendors in the U.S. Automated Cell Counting Market & Their Offerings

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis

Strengths

• Strong presence of biotechnology and pharmaceutical companies supporting demand for advanced cell analysis tools.
• Well-established research infrastructure and funding for life science and biomedical research.
• High adoption of advanced laboratory technologies and automation in research and clinical laboratories.
• The presence of major industry players such as Thermo Fisher Scientific and Bio-Rad Laboratories is driving innovation.

Weaknesses

• High cost of automated cell counting instruments and maintenance.
• Dependence on skilled laboratory professionals for proper system operation and data interpretation.
• Integration challenges with existing laboratory workflows and systems.
• Smaller laboratories may face budget limitations when adopting advanced automated systems.

Opportunities

• Increasing research in biologics, regenerative medicine, and cell-based therapies.
• Rising demand for accurate and high-throughput cell analysis in drug discovery.
• Growing investments in biotechnology startups and research institutions.
• Continuous development of more compact, efficient, and user-friendly automated cell counting technologies.

Threats

• Availability of alternative cell analysis methods, such as flow cytometry.
• Strict regulatory requirements for laboratory instruments and diagnostic technologies.
• Budget constraints in academic and smaller research laboratories.
• Intense competition among major companies such as Danaher Corporation and Agilent Technologies.

Latest Announcement by the Industry Leaders

• In December 2025, "The BD FACSDiscover™ A8 Cell Analyzer has become our new standard, changing how our flow cytometry core operates," said Gert Van Isterdael, head of VIB Flow Core Ghent. "Once you experience the integration of spectral and imaging data, you don't want to go back. It opens a new dimension for our work, helping us see more, understand faster, and enable discoveries that simply weren't possible before. The BD FACSDiscover™ A8 Cell Analyzer is a game changer, and having more configurations will only make this leading technology more accessible to a wider range of labs."
• In July 2025, “as we continue to expand the applications available on CellDrop, we’re excited to make robust technology available to a broader number of research labs. We continue to work hard to deliver exciting new applications on the CellDrop platform to expand the capabilities for new and existing customers,” said Andrew Jones, Market Development Manager, DeNovix, Inc.

What are the Recent Developments in the U.S. Automated Cell Counting Market?

• In January 2025, Thermo Fisher Scientific introduced an upgraded automated cell counting system designed to improve counting precision and simplify cell analysis workflows for biotechnology and pharmaceutical research laboratories.
• In July 2025, DeNovix enhanced its automated cell counting technology with additional analysis features to support specialized applications such as stem cell studies and advanced laboratory research.

Segments Covered in the Report

By-Product

• Consumables & Accessories
• Instruments
• Flow Cytometers
• Image-based Cell Counters
• Electrical Impedance Coulter Counters

By Application

• Cell Line Development
• Biologics Production
• Cell & Gene Therapy
• Stem Cell Research
• Blood Analysis
• Others

By End Use

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes
• Others